Clinical Trials Browser

NCT05564403 2026-05-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Phase 2 Active not recruiting

66 enrolled

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05836584 2026-05-13

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2 Active not recruiting

240 enrolled

Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

NCT06094140 2026-05-06

NEO-IMPACT

Phase 2 Active not recruiting

20 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-04-29

EDGE-Gastric

Phase 2 Active not recruiting

332 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Clinical Stage 0 Gastric Cancer AJCC v8

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Phase 2 Active not recruiting

66 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Phase 2 Active not recruiting

43 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT03764553 2026-04-07

LyRICX

Phase 2 Active not recruiting

320 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

143 enrolled

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT04245865 2026-04-03

Toco-CoR

Phase 2 Active not recruiting

83 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

40 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2 Active not recruiting

226 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04757363 2026-03-04

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Phase 2 Active not recruiting

39 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05466799 2026-02-13

TRIPP-FFX

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Locally Advanced Pancreatic Cancer

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT06268015 2026-02-05

BBOpCo

Phase 2 Active not recruiting

16 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2 Active not recruiting

80 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

66 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00335816 2026-01-14

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Phase 2 Active not recruiting

248 enrolled

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Phase 2 Active not recruiting

42 enrolled 13 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT05504252 2026-01-07

METIMMOX-2

Phase 2 Active not recruiting

80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

NCT05382442 2025-10-14

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Phase 2 Active not recruiting

254 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06124378 2025-09-24

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Phase 2 Active not recruiting

60 enrolled

Gastrointestinal

Colonic Neoplasms

NCT03110926 2025-09-12

Induction Chemotherapy for Locally Advanced Esophageal Cancer

Phase 2 Active not recruiting

40 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05610163 2025-09-08

JANUS

Phase 2 Active not recruiting

783 enrolled

Gastrointestinal

Rectal Neoplasms

NCT02008656 2025-08-27

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Phase 2 Active not recruiting

358 enrolled

Gastrointestinal

Rectal Neoplasms

NCT00492999 2025-08-17

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2 Active not recruiting

64 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03493048 2025-08-03

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

Phase 2 Active not recruiting

146 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07090031 2025-07-29

Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

49 enrolled

EFS

NCT03421288 2025-07-25

DANTE

Phase 2 Active not recruiting

677 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05253846 2025-06-10

ShorTrip

Phase 2 Active not recruiting

63 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT03448835 2025-06-08

PANDA

Phase 2 Active not recruiting

20 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04251715 2025-04-18

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Phase 2 Active not recruiting

5 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT02980510 2025-02-20

PANIRINOX

Phase 2 Active not recruiting

219 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03255434 2025-02-13

LEANOX

Phase 2 Active not recruiting

160 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06766019 2025-01-09

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

Phase 2 Active not recruiting

47 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01531595 2024-12-12

AXOAXI

Phase 2 Active not recruiting

100 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Phase 2 Active not recruiting

50 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04515615 2024-09-19

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

Phase 2 Active not recruiting

52 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04672005 2024-05-16

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02931890 2024-05-02

CRITICS-II

Phase 2 Active not recruiting

207 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03950271 2024-02-28

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

25 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04304209 2023-02-01

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

195 enrolled

Gastrointestinal

Colorectal Neoplasms